Iradimed Corp (IRMD) Stock Price & Analysis
Iradimed Corp (IRMD) rose 2.15% to USD 96.42 as of June 10, 2026 at 08:35 UTC, according to Nexqual real-time market data.
IRMD last closed at USD 94.39; the session ranged USD 94.85–96.74 on volume of 153,908 shares. Market capitalization is $1.23B, with a 52-week range of USD 55.11–107.9 (NGM). Source: Nexqual, June 10, 2026 at 08:35 UTC.
Key Statistics (as of June 10, 2026 at 08:35 UTC)
| Price | USD 96.42 |
|---|---|
| Change | ▲ 2.15% (up) |
| Previous Close | USD 94.39 |
| Open | USD 94.98 |
| Day Range | USD 94.85 – 96.74 |
| 52-Week Range | USD 55.11 – 107.9 |
| Volume | 153,908 shares |
| Market Cap | $1.23B |
| Exchange | NGM |
Technical Analysis (IRMD)
Nexqual's technical model rates IRMD "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 08:35 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.44 (neutral) |
| vs SMA50 | Above (USD 90.62) |
| MACD | 0.98 (positive) |
Analyst Ratings (IRMD)
Wall Street analysts rate IRMD "None" based on 2 analysts, with a mean price target of USD 118 (range USD 116–120), per Nexqual as of June 10, 2026 at 08:35 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 118 |
| High Target | USD 120 |
| Low Target | USD 116 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (IRMD)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 0.44 |
| Revenue Estimate | $20.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.49 vs est 0.45 ▲ beat |
| 2025-12-31 | USD 0.54 vs est 0.48 ▲ beat |
| 2025-09-30 | USD 0.47 vs est 0.46 ▲ beat |
| 2025-06-30 | USD 0.49 vs est 0.44 ▲ beat |
Source: Nexqual, June 10, 2026 at 08:35 UTC.
Financials & Fundamentals (IRMD)
| Total Revenue | $86.28M |
|---|---|
| Revenue Growth (YoY) | +12.60% |
| Gross Margin | +76.83% |
| Operating Margin | +32.93% |
| Profit Margin | +27.37% |
| ROE | +25.04% |
| Current Ratio | 7.13 |
| Total Cash | $56.37M |
| Total Debt | $0 |
| Free Cash Flow | $15.16M |
Source: Nexqual, June 10, 2026 at 08:35 UTC.
Financial Health Score (IRMD)
Nexqual rates Iradimed Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 08:35 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 77%, operating 33% |
| Balance Sheet | Mixed — $56M cash, no debt |
| Cash Flow | Strong — FCF $15M, 18% margin |
| Efficiency | Strong — ROE 25%, ROA 16.2% |
Ownership (IRMD)
| Insider Ownership | +35.20% |
|---|---|
| Institutional Ownership | +61.02% |
| Shares Outstanding | 12.78M |
| Float | 8.32M |
| Short % of Float | +7.88% |
Source: Nexqual, June 10, 2026 at 08:35 UTC.
Leadership (IRMD)
Iradimed Corp is led by Roger E. Susi (age 72), Founder, Chairman, CEO & President, per Nexqual as of June 10, 2026 at 08:35 UTC.
| Founder, Chairman, CEO & President | Roger E. Susi (age 72) |
|---|---|
| CFO & Corporate Secretary | John F. Glenn (age 63) |
| Vice President of Worldwide Sales & Marketing | Randy Waddell |
| Executive Vice President of Continuous Improvement & Information Technology | Chris Williamson |
| Vice President of Research & Development | Lynn Neuhardt |
Major Backers & Investors (IRMD)
Notable institutional backers of Iradimed Corp include Renaissance Technologies, Copeland Capital Management, LLC, Kayne Anderson Rudnick Investment Management LLC, according to Nexqual as of June 10, 2026 at 08:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 3.45% |
| Copeland Capital Management, LLC | 2.81% |
| Kayne Anderson Rudnick Investment Management LLC | 2.73% |
| T. Rowe Price | 2.65% |
| Nine Ten Capital Management LLC | 2.62% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.58% |
| Vanguard Group | 5.55% |
| Geode Capital | 2.24% |
| Dimensional Fund Advisors | 1.77% |
| State Street | 1.6% |
Source: Nexqual, June 10, 2026 at 08:35 UTC.
From Iradimed Corp's Latest SEC 10-K Filing (filed 2026-03-06)
Key Strengths & Strategy (as disclosed to the SEC)
- IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.
- The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
- It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.
- The company serves hospitals, acute care facilities, and outpatient imaging centers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LMAT | LeMaitre Vascular, Inc. | USD 96.59 | ▲ 2.23% |
| KIDS | OrthoPediatrics Corp. | USD 18.49 | ▲ 0.93% |
| JYNT | The Joint Corp. | USD 8.41 | ▲ 1.45% |
| UFPT | UFP Technologies, Inc. | USD 231.12 | ▲ 3.24% |
| PAHC | Phibro Animal Health Corporatio | USD 32.65 | ▲ 0.68% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:35 UTC. This page is informational and not investment advice.